Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice.

Karlin J, Allen J, Ahmad SF, Hughes G, Sheridan V, Odedra R, Farrington P, Cadogan EB, Riches LC, Garcia-Trinidad A, Thomason AG, Patel B, Vincent J, Lau A, Pike KG, Hunt TA, Sule A, Valerie NCK, Biddlestone-Thorpe L, Kahn J, Beckta JM, Mukhopadhyay N, Barlaam B, Degorce SL, Kettle J, Colclough N, Wilson J, Smith A, Barrett IP, Zheng L, Zhang T, Wang Y, Chen K, Pass M, Durant ST, Valerie K.

Mol Cancer Ther. 2018 Aug;17(8):1637-1647. doi: 10.1158/1535-7163.MCT-17-0975. Epub 2018 May 16.

PMID:
29769307
2.

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.

Floc'h N, Ashton S, Taylor P, Trueman D, Harris E, Odedra R, Maratea K, Derbyshire N, Caddy J, Jacobs VN, Hattersley M, Wen S, Curtis NJ, Pilling JE, Pease EJ, Barry ST.

Mol Cancer Ther. 2017 Jun;16(6):1031-1040. doi: 10.1158/1535-7163.MCT-16-0580. Epub 2017 Mar 14.

3.

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.

Oplustil O'Connor L, Rulten SL, Cranston AN, Odedra R, Brown H, Jaspers JE, Jones L, Knights C, Evers B, Ting A, Bradbury RH, Pajic M, Rottenberg S, Jonkers J, Rudge D, Martin NM, Caldecott KW, Lau A, O'Connor MJ.

Cancer Res. 2016 Oct 15;76(20):6084-6094. Epub 2016 Aug 22.

4.

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.

Ashton S, Song YH, Nolan J, Cadogan E, Murray J, Odedra R, Foster J, Hall PA, Low S, Taylor P, Ellston R, Polanska UM, Wilson J, Howes C, Smith A, Goodwin RJ, Swales JG, Strittmatter N, Takáts Z, Nilsson A, Andren P, Trueman D, Walker M, Reimer CL, Troiano G, Parsons D, De Witt D, Ashford M, Hrkach J, Zale S, Jewsbury PJ, Barry ST.

Sci Transl Med. 2016 Feb 10;8(325):325ra17. doi: 10.1126/scitranslmed.aad2355.

5.

Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055.

Keen HG, Ricketts SA, Maynard J, Logie A, Odedra R, Shannon AM, Wedge SR, Guichard SM.

Mol Imaging Biol. 2014 Jun;16(3):421-30. doi: 10.1007/s11307-013-0705-0.

PMID:
24249640
6.

Global metabolite profiling of human colorectal cancer xenografts in mice using HPLC-MS/MS.

Loftus NJ, Lai L, Wilkinson RW, Odedra R, Wilson ID, Barnes AJ.

J Proteome Res. 2013 Jun 7;12(6):2980-6. doi: 10.1021/pr400260h. Epub 2013 May 22.

PMID:
23631600
7.

Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.

Foote KM, Blades K, Cronin A, Fillery S, Guichard SS, Hassall L, Hickson I, Jacq X, Jewsbury PJ, McGuire TM, Nissink JW, Odedra R, Page K, Perkins P, Suleman A, Tam K, Thommes P, Broadhurst R, Wood C.

J Med Chem. 2013 Mar 14;56(5):2125-38. doi: 10.1021/jm301859s. Epub 2013 Mar 1.

PMID:
23394205
8.

Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.

Kendrew J, Odedra R, Logié A, Taylor PJ, Pearsall S, Ogilvie DJ, Wedge SR, Jürgensmeier JM.

Cancer Chemother Pharmacol. 2013 Apr;71(4):1021-32. doi: 10.1007/s00280-013-2097-x. Epub 2013 Jan 26.

PMID:
23355042
9.

Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia.

Alferez DG, Goodlad RA, Odedra R, Sini P, Crafter C, Ryan AJ, Wedge SR, Wright NA, Anderson E, Wilkinson RW.

Int J Oncol. 2012 Oct;41(4):1475-85. doi: 10.3892/ijo.2012.1580. Epub 2012 Jul 31.

PMID:
22858681
10.

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.

Holt SV, Logié A, Odedra R, Heier A, Heaton SP, Alferez D, Davies BR, Wilkinson RW, Smith PD.

Br J Cancer. 2012 Feb 28;106(5):858-66. doi: 10.1038/bjc.2012.8. Epub 2012 Feb 16.

11.

Metal organic chemical vapour deposition of vertically aligned ZnO nanowires using oxygen donor adducts.

Hindley S, Jones AC, Ashraf S, Bacsa J, Steiner A, Chalker PR, Beahan P, Williams PA, Odedra R.

J Nanosci Nanotechnol. 2011 Sep;11(9):8294-301.

PMID:
22097572
12.

Ce(IV) complexes with donor-functionalized alkoxide ligands: improved precursors for chemical vapor deposition of CeO2.

Aspinall HC, Bacsa J, Jones AC, Wrench JS, Black K, Chalker PR, King PJ, Marshall P, Werner M, Davies HO, Odedra R.

Inorg Chem. 2011 Nov 21;50(22):11644-52. doi: 10.1021/ic201593s. Epub 2011 Oct 21.

PMID:
22017450
13.

The solid-state structures of dimethylzinc and diethylzinc.

Bacsa J, Hanke F, Hindley S, Odedra R, Darling GR, Jones AC, Steiner A.

Angew Chem Int Ed Engl. 2011 Dec 2;50(49):11685-7. doi: 10.1002/anie.201105099. Epub 2011 Sep 14. No abstract available.

14.

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.

Brave SR, Odedra R, James NH, Smith NR, Marshall GB, Acheson KL, Baker D, Howard Z, Jackson L, Ratcliffe K, Wainwright A, Lovick SC, Hickinson DM, Wilkinson RW, Barry ST, Speake G, Ryan AJ.

Int J Oncol. 2011 Jul;39(1):271-8. doi: 10.3892/ijo.2011.1022. Epub 2011 Apr 29.

PMID:
21537841
15.

Synthesis and structure of 6-aminofulvene-2-aldiminate complexes.

Willcocks AM, Gilbank A, Richards SP, Brayshaw SK, Kingsley AJ, Odedra R, Johnson AL.

Inorg Chem. 2011 Feb 7;50(3):937-48. doi: 10.1021/ic101524b. Epub 2011 Jan 5.

PMID:
21207947
16.

Methodological considerations in the development of HPLC-MS methods for the analysis of rodent plasma for metabonomic studies.

Lai L, Michopoulos F, Gika H, Theodoridis G, Wilkinson RW, Odedra R, Wingate J, Bonner R, Tate S, Wilson ID.

Mol Biosyst. 2010 Jan;6(1):108-20. doi: 10.1039/b910482h. Epub 2009 Sep 4.

PMID:
20024072
17.

Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker.

Olofsson MH, Cummings J, Fayad W, Brnjic S, Herrmann R, Berndtsson M, Hodgkinson C, Dean E, Odedra R, Wilkinson RW, Mundt KE, Busk M, Dive C, Linder S.

Cancer Biomark. 2009;5(3):117-25. doi: 10.3233/CBM-2009-0597.

PMID:
19407366
18.

AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.

Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, Fitzgibbon J, Lister AT, Joel S, Bonnet D.

Cancer Res. 2009 May 15;69(10):4150-8. doi: 10.1158/0008-5472.CAN-08-3203. Epub 2009 Apr 14.

19.

Unprecedented double migratory insertion of phenyl isocyanide into cyclopentadienyl C-H bonds.

Johnson AL, Willcocks AM, Raithby PR, Warren MR, Kingsley AJ, Odedra R.

Dalton Trans. 2009 Feb 14;(6):922-4. doi: 10.1039/b822337h. Epub 2009 Jan 6.

PMID:
19173073
20.

Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.

Bradley DP, Tessier JJ, Lacey T, Scott M, Jürgensmeier JM, Odedra R, Mills J, Kilburn L, Wedge SR.

Magn Reson Imaging. 2009 Apr;27(3):377-84. doi: 10.1016/j.mri.2008.07.021. Epub 2008 Sep 23.

PMID:
18814988
21.

CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.

Krige D, Needham LA, Bawden LJ, Flores N, Farmer H, Miles LE, Stone E, Callaghan J, Chandler S, Clark VL, Kirwin-Jones P, Legris V, Owen J, Patel T, Wood S, Box G, Laber D, Odedra R, Wright A, Wood LM, Eccles SA, Bone EA, Ayscough A, Drummond AH.

Cancer Res. 2008 Aug 15;68(16):6669-79. doi: 10.1158/0008-5472.CAN-07-6627.

22.

Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity.

Cummings J, Hodgkinson C, Odedra R, Sini P, Heaton SP, Mundt KE, Ward TH, Wilkinson RW, Growcott J, Hughes A, Dive C.

Mol Cancer Ther. 2008 Mar;7(3):455-63. doi: 10.1158/1535-7163.MCT-07-2136.

23.

Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity.

Foote KM, Mortlock AA, Heron NM, Jung FH, Hill GB, Pasquet G, Brady MC, Green S, Heaton SP, Kearney S, Keen NJ, Odedra R, Wedge SR, Wilkinson RW.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1904-9. doi: 10.1016/j.bmcl.2008.02.002. Epub 2008 Feb 7.

PMID:
18294849
24.

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.

Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S.

Clin Cancer Res. 2007 Jun 15;13(12):3682-8.

25.

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S.

J Med Chem. 2007 May 3;50(9):2213-24. Epub 2007 Mar 21.

PMID:
17373783
26.

Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.

Jung FH, Pasquet G, Lambert-van der Brempt C, Lohmann JJ, Warin N, Renaud F, Germain H, De Savi C, Roberts N, Johnson T, Dousson C, Hill GB, Mortlock AA, Heron N, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Green S, Brown E, Thompson K, Brightwell S.

J Med Chem. 2006 Feb 9;49(3):955-70.

PMID:
16451062
27.

Multiplex PCRs for identification of Escherichia coli virulence genes.

Pass MA, Odedra R, Batt RM.

J Clin Microbiol. 2000 May;38(5):2001-4.

28.

Evidence for a compensatory increase in synthesis of brush border enzymes in the jejunum of Irish Setters with gluten-sensitive enteropathy.

Manners HK, Sørensen SH, Embaye H, Odedra RM, Batt RM.

Am J Vet Res. 1998 Nov;59(11):1392-7.

PMID:
9829395
29.

Surface properties of diarrhoeagenic Escherichia coli isolates.

Fletcher JN, Saunders JR, Embaye H, Odedra RM, Batt RM, Hart CA.

J Med Microbiol. 1997 Jan;46(1):67-74.

PMID:
9003748
30.

Growth and propagation of normal rat intestinal epithelial cells.

Odedra RM, Hart CA, Saunders JR, Getty B, van de Wall S, Sorensen SH, Embaye H, Batt RM.

In Vitro Cell Dev Biol Anim. 1996 Feb;32(2):107-115.

PMID:
8907124
31.

Effects of concanavalin A and pokeweed lectins on microvillar membrane proteins during the organ culture of rabbit intestinal mucosa.

Embaye H, Whybrew L, Odedra RM, Hart CA, Fletcher JN, Saunders JR, Batt RM.

Res Vet Sci. 1995 Jul;59(1):50-5.

PMID:
8525086
33.

Low molecular weight angiogenesis factors.

Odedra R, Weiss JB.

Pharmacol Ther. 1991;49(1-2):111-24. Review.

PMID:
1712974
35.

Angiogenic factor in ocular fluid.

Weiss JB, Taylor CM, Wiseman D, Odedra R, Elstow S.

Lancet. 1985 Nov 23;2(8465):1190-1. No abstract available.

PMID:
2865646

Supplemental Content

Loading ...
Support Center